Compare · ABBV vs PBYI
ABBV vs PBYI
Side-by-side comparison of AbbVie Inc. (ABBV) and Puma Biotechnology Inc (PBYI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and PBYI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $449.63B, about 1035.6x PBYI ($434.2M).
- Over the past year, ABBV is up 34.5% and PBYI is up 150.7% - PBYI leads by 116.3 points.
- ABBV has been more active in the news (23 items in the past 4 weeks vs 5 for PBYI).
- ABBV has more recent analyst coverage (25 ratings vs 4 for PBYI).
- Company
- AbbVie Inc.
- Puma Biotechnology Inc
- Price
- $254.52+0.06%
- $8.53+1.25%
- Market cap
- $449.63B
- $434.2M
- 1M return
- +14.38%
- +18.73%
- 1Y return
- +34.48%
- +150.74%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 23
- 5
- Recent ratings
- 25
- 4
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest PBYI
- President and CEO Auerbach Alan H sold $364,051 worth of shares (44,058 units at $8.26) as part of a pre-agreed trading plan, decreasing direct ownership by 0.60% to 7,261,671 units (SEC Form 4)
- Officer Hunt Douglas M sold $69,905 worth of shares (8,460 units at $8.26) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 196,841 units (SEC Form 4)
- Chief Financial Officer Nougues Maximo F sold $77,557 worth of shares (9,386 units at $8.26) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 230,637 units (SEC Form 4)
- SEC Form 144 filed by Puma Biotechnology Inc
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Wilson Troy Edward was granted 27,000 shares and sold $77,748 worth of shares (10,800 units at $7.20) as part of a pre-agreed trading plan, increasing direct ownership by 37% to 59,750 units (SEC Form 4)
- Director Stuglik Brian M was granted 27,000 shares and sold $58,311 worth of shares (8,100 units at $7.20) as part of a pre-agreed trading plan, increasing direct ownership by 20% to 113,858 units (SEC Form 4)
- Director Senderowicz Adrian sold $194,311 worth of shares (27,000 units at $7.20) as part of a pre-agreed trading plan and was granted 27,000 shares (SEC Form 4)
- Director Miller Michael Patrick was granted 27,000 shares, increasing direct ownership by 50% to 81,000 units (SEC Form 4)